185 related articles for article (PubMed ID: 30894110)
1. Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.
Yousuf M
Curr Cancer Drug Targets; 2019; 19(11):906-918. PubMed ID: 30894110
[TBL] [Abstract][Full Text] [Related]
2. Potential Biological Targets Prediction,
Yousuf M; Rafi S; Ishrat U; Shafiga A; Dashdamirova G; Leyla V; Iqbal H
Med Chem; 2022; 18(2):288-305. PubMed ID: 34102986
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors.
Yousuf M; Shaikh NN; Ul-Haq Z; Choudhary MI
PLoS One; 2018; 13(12):e0200502. PubMed ID: 30517092
[TBL] [Abstract][Full Text] [Related]
4. Synthesis,
Alam W; Khan H; Saeed Jan M; Rashid U; Abusharha A; Daglia M
Front Chem; 2023; 11():1222047. PubMed ID: 37744065
[TBL] [Abstract][Full Text] [Related]
5. Discovery of specific inhibitors for intestinal E. coli β-glucuronidase through in silico virtual screening.
Cheng TC; Chuang KH; Roffler SR; Cheng KW; Leu YL; Chuang CH; Huang CC; Kao CH; Hsieh YC; Chang LS; Cheng TL; Chen CS
ScientificWorldJournal; 2015; 2015():740815. PubMed ID: 25839056
[TBL] [Abstract][Full Text] [Related]
6. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules.
Daina A; Zoete V
ChemMedChem; 2016 Jun; 11(11):1117-21. PubMed ID: 27218427
[TBL] [Abstract][Full Text] [Related]
7. Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
Azad I; Nasibullah M; Khan T; Hassan F; Akhter Y
J Mol Graph Model; 2018 May; 81():211-228. PubMed ID: 29609141
[TBL] [Abstract][Full Text] [Related]
8. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
[TBL] [Abstract][Full Text] [Related]
9. Progress in predicting human ADME parameters in silico.
Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in silico studies of novel sulfonamides having oxadiazole ring: As β-glucuronidase inhibitors.
Taha M; Baharudin MS; Ismail NH; Selvaraj M; Salar U; Alkadi KA; Khan KM
Bioorg Chem; 2017 Apr; 71():86-96. PubMed ID: 28160943
[TBL] [Abstract][Full Text] [Related]
11. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.
Daina A; Michielin O; Zoete V
Sci Rep; 2017 Mar; 7():42717. PubMed ID: 28256516
[TBL] [Abstract][Full Text] [Related]
12. 2-Oxo-1,2,3,4-tetrahydropyrimidines Ethyl Esters as Potent β- Glucuronidase Inhibitors: One-pot Synthesis, In vitro and In silico Studies.
Iqbal S; Shaikh NN; Khan KM; Naz S; Ul-Haq Z; Perveen S; Choudhary MI
Med Chem; 2018; 14(8):818-830. PubMed ID: 29793412
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro β-glucuronidase inhibitory activity and in silico studies of novel (E)-4-Aryl-2-(2-(pyren-1-ylmethylene)hydrazinyl)thiazoles.
Salar U; Khan KM; Syed S; Taha M; Ali F; Ismail NH; Perveen S; Wadood A; Ghufran M
Bioorg Chem; 2017 Feb; 70():199-209. PubMed ID: 28069264
[TBL] [Abstract][Full Text] [Related]
14. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the thiazole Schiff bases as β-glucuronidase inhibitors and their in silico studies.
Khan KM; Karim A; Saied S; Ambreen N; Rustamova X; Naureen S; Mansoor S; Ali M; Perveen S; Choudhary MI; Morales GA
Mol Divers; 2014 May; 18(2):295-306. PubMed ID: 24535226
[TBL] [Abstract][Full Text] [Related]
16. In silico ADME/T modelling for rational drug design.
Wang Y; Xing J; Xu Y; Zhou N; Peng J; Xiong Z; Liu X; Luo X; Luo C; Chen K; Zheng M; Jiang H
Q Rev Biophys; 2015 Nov; 48(4):488-515. PubMed ID: 26328949
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Disubstituted thiadiazoles as potent β-glucuronidase inhibitors; Synthesis, in vitro and in silico studies.
Taha M; Barak Almandil N; Rashid U; Ali M; Ibrahim M; Gollapalli M; Mosaddik A; Mohammed Khan K
Bioorg Chem; 2019 Oct; 91():103126. PubMed ID: 31349116
[TBL] [Abstract][Full Text] [Related]
18. In silico ADME/Tox: the state of the art.
Ekins S; Rose J
J Mol Graph Model; 2002 Jan; 20(4):305-9. PubMed ID: 11858639
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
[TBL] [Abstract][Full Text] [Related]
20. Predicting ADME properties and side effects: the BioPrint approach.
Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
